Glioma
Conditions
Brief summary
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas
Detailed description
Amino acid PET imaging could represent a biomarker for the evaluation of IDH inhibitor treatments for patients with refractory IDH-mutated gliomas In fact, this study will allow us to assess, using Rano 1.0 criteria for PET and Rano 2.0 criteria for MRI, which of the two examinations is most effective in assessing the efficacy of anti-IDH treatment patients with refractory IDH-mutated gliomas.
Interventions
OTHERAmino-acid PET
Patients received 18-fluoroDopa then a PET exam
Sponsors
Central Hospital, Nancy, France
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients who underwent amino acid PET for early assessment of therapeutic response of IDH-mutated gliomas under anti-IDH treatment between February 2022 and November 2024
Exclusion criteria
* Individuals who have objected to the use of their data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy | one day | Comparison between early therapeutic response according to RANO 1.0 and RANO 2.0 PET criteria and tumor progression at 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compare the performance between amino acid PET and brain MRI to assess a treatment efficacy for the identification of lesions | one day | Determination of the number of lesions assessable by amino acid PET according to RANO 1.0 PET criteria and by MRI according to RANO 2.0 criteria |
Countries
France
Outcome results
None listed